Table 1.
Clinicopathological features of original biliary tract tumors
| Xenograft | Pathological diagnosis of original tumor | Age/sex | Histologic type | Prognosis (survival days) | Chemotherapy | Clinical evaluation of chemotherapy effect (effective days) | Established cell line |
| 1 | CCC | 70/F | Adeno, mod | Death (402) | Non | NCC-CC1 | |
| 2 | CCC | 71/F | Adeno, mod | Death (175) | Non | NCC-CC3-1 | |
| NCC-CC3-2 | |||||||
| 3 | CCC | 59/M | Adeno, mod | Alive (2172) | Non | NCC-CC4-1 | |
| NCC-CC4-2 | |||||||
| NCC-CC4-3(NCC-CC5) | |||||||
| 4 | CCC | 31/M | Adeno, mod + PSC | Death (386) | GEM + TS1 | SD (84 d) | NCC-CC6-1 |
| NCC-CC6-2 | |||||||
| 5 | Distal BDCa | 58/F | Adeno, mod | Death (299) | GEM | PD | NCC-BD1 |
| 6 | Distal BDCa | 77/F | Adeno, mod | Death (393) | GEM | PD | NCC-BD21 |
| 7 | Distal BDCa | 80/M | Adeno, mod | Death (212) | Non | NCC-BD3 | |
| 8 | Hilar BDCa | 74/M | Adeno, mod | Death (172) | Non | NCC-BD4-1 | |
| NCC-BD4-2 | |||||||
| 9 | Hilar BDCa | 48/M | Adeno, well | Alive (500) | GEM | PD | NA |
| 10 | Hilar BDCa | 43/M | Adeno, mod | Alive (1422) | Non | NA | |
| 11 | CCC | 69/M | Adeno, mod | Death (174) | Non | NA | |
| 12 | CCC | 54/F | Adeno, mod | Death (181) | Non | NA | |
| 13 | CCC | 56/M | Adeno, mod | Death (319) | GEM | PD | NA |
| 14 | CCC | 73/M | Adeno, mod | Death (53) | Non | NA | |
| 15 | CCC | 54/M | Adeno, mod | Alive (2608) | Non | NA | |
| 16 | CCC | 45/F | Adeno, mod | Alive (882) | GEM + CDDP | Unknown | NA |
| 17 | CCC | 72/M | Muc | Death (749) | GEM/GEM + TS1 | Unknown | NA |
| 18 | CCC | 78/M | Adeno, mod | Death (382) | GEM | Unknown | NA |
| 19 | CCC | 66/M | Adeno, mod | Death (168) | Non | NA | |
| 20 | CCC | 65/M | CoCC | Alive (1604) | Non | NA | |
| 21 | CCC | 70/M | Adeno, por | Death (851) | GEM | SD (49 d) | NA |
| 22 | CCC | 63/F | Adeno, mod | Alive (363) | Unknown | Unknown | NA |
| 23 | CCC | 72/M | Adeno, mod | Death (394) | GEM | PD | NA |
| 24 | CCC | 77/F | Adeno, mod | Death (445) | GEM | SD (105 d) | NA |
| 25 | Hilar BDCa | 66/M | Adeno, mod | Alive (102) | GEM + TS1 | Unknown | NA |
| 26 | Distal BDCa | 54/M | Adeno, mod | Alive (2096) | Non | NA | |
| 27 | Distal BDCa | 67/M | Adeno, mod | Death (672) | GEM + TS1 | PD | NA |
| 28 | Distal BDCa | 80/M | Adeno, mod | Alive (2024) | GEM | PR-CR (548 d) | NA |
1
BD2 was obtained from the direct culture of patient specimens. CCC: Cholangiocellular carcinoma; BDCa: Bile duct carcinoma; Adeno: Adenocarcinoma; mod: Moderately differentiated; PSC: Primary sclerosing cholangitis; Muc: Mucinous carcinoma; CoCC: Cholangiolocellular carcinoma; por: Poorly differentiated; non: No chemotherapy received; GEM: Gemcitabine; CDDP: Cisplatin; SD: Stable disease; PD: Progressive disease; PR: Partial response; CR: Complete response.